Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Mendoza

Neurology Augusta, GA Medical Doctor

NPI 1699813741 CMS profile 781738

3556 Pebble Beach Dr, Augusta, GA 30907

Open in the dashboard

General payments

$9,600

446 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Mendoza of Augusta, GA is reported in the CMS Open Payments database as having received $9,600 across 446 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,131 96
2024 General $2,390 100
2023 General $2,096 98
2022 General $1,338 79
2021 General $1,199 65
2020 General $78 4
2019 General $367 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Mendoza
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Edward Mendoza were reported at $2,131. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Edward Mendoza Neurology median Middle half National median
2019 $367 $474 $118–$2,177 $163
2020 $78 $367 $82–$2,309 $114
2021 $1,199 $438 $104–$2,547 $132
2022 $1,338 $442 $103–$2,388 $149
2023 $2,096 $464 $119–$2,312 $160
2024 $2,390 $468 $119–$2,323 $164
2025 $2,131 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,416 100 payments
  2. EMD Serono, Inc. $1,330 61 payments
  3. UCB, Inc. $1,285 42 payments
  4. Biogen, Inc. $622 29 payments
  5. Novartis Pharmaceuticals Corporation $581 34 payments
  6. Alexion Pharmaceuticals, Inc. $368 15 payments
  7. Lundbeck LLC $280 13 payments
  8. Amneal Pharmaceuticals LLC $275 13 payments
  9. Argenx US, Inc. $258 9 payments
  10. SK Life Science, Inc. $234 11 payments
  11. Other $2,951 119 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,586 444 payments
  2. Education $14 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $904 64 payments
  2. QULIPTA $867 61 payments
  3. Rystiggo $750 21 payments
  4. KESIMPTA $463 26 payments
  5. MAVENCLAD Neurology $444 23 payments
  6. VUMERITY $323 20 payments
  7. BRIUMVI $230 9 payments
  8. Briviact $218 10 payments
  9. TYSABRI $209 13 payments
  10. Mavenclad Neurology $207 2 payments
  11. Other $5,665 226 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,640

Median for Neurology: 833

Drug cost

$113,517

Median for Neurology: $202,670

Branded share of claims

25.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 20 $32,534
Emgality Pen Galcanezumab-Gnlm Brand 29 $27,564
Aimovig Autoinjector Erenumab-Aooe Brand 32 $24,504
Gabapentin Generic 313 $5,713
Carbidopa-Levodopa Carbidopa/Levodopa Brand 181 $4,561
Entacapone Generic 19 $2,558
Primidone Generic 113 $2,192
Propranolol Hcl Er Propranolol Hcl Brand 62 $1,752
Amantadine Amantadine Hcl Brand 30 $1,294
Topiramate Generic 169 $1,287

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$11,783

Medicare's payments for the services billed

Medicare patients

153

Average age 72

Services billed

200

95 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Depression 40%
Ischemic heart disease 39%
Diabetes 31%
COPD 21%
Heart failure 18%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Rystiggo
  • UCB, Inc. $496
$496 — —
Leqembi
  • Eisai Inc. $154
$154 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $145
$145 — —
UBRELVY
  • AbbVie, Inc. $129
$129 — —
QULIPTA
  • AbbVie, Inc. $127
$127 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

446 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record